GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
April 29, 2024 16:05 ET
|
GeneDx Holdings Corp.
GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the first quarter of 2024.
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
April 23, 2024 08:30 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with...
GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
April 04, 2024 16:05 ET
|
GeneDx Holdings Corp.
Management will host a conference call on Monday, April 29, 2024 to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.
GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics
March 14, 2024 08:30 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at...
GeneDx to Participate in 44th Annual Cowen Health Care Conference
February 26, 2024 16:05 ET
|
GeneDx Holdings Corp.
GeneDx (Nasdaq: WGS) today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA.
GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
February 20, 2024 16:26 ET
|
GeneDx Holdings Corp.
GeneDx Holdings Corp. (Nasdaq: WGS) reported its financial results for the fourth quarter and full year of 2023.
GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024
February 01, 2024 16:30 ET
|
GeneDx Holdings Corp.
GeneDx management will host a conference call at 4:30 p.m. Eastern Time on February 20, 2024 to discuss 2023 results and share full year 2024 guidance.
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 24, 2024 16:30 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23,...
GeneDx Announces Preliminary 2023 Financial Results
January 08, 2024 08:55 ET
|
GeneDx Holdings Corp.
Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations of more than $57M.
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
December 01, 2023 08:30 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Dec. 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced new data to be...